Facebook-f Linkedin Twitter

CONFERENCE COVERAGE: 64th American Society of Hematology (ASH) Annual Meeting

  1. AbbVie Presents Data Adds to Robust IMBRUVICA® (ibrutinib) Science
  2. AbbVie Presents Data of Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
  3. AbbVie Presents Data for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
  4. Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
  5. Affimed provides updated clinical data from Ph 1/2 study of AFM13 precomplexed with cord blood-derived NKcells
  6. Body Of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta CAR T-Cell Therapy For Patients With R/R Large B-Cell Lymphoma
  7. Genentech Presents New and Updated Data for Polivy in 1L DLBCL
  8. Genmab Showcases Data From Epcoritamab (DuoBody-CD3xCD20) program in Patients Across a Broad Range of B-Cell Lymphomas
  9. Harpoon Therapeutics Presents Updated Interim Results for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
  10. IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies
  11. Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) + DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
  12. Janssen Presents New Data for Talquetamab Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
  13. Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib
  14. LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051
  15. MorphoSys Presents New Longer-term Ph 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity
  16. MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis
  17. New data underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
  18. New Results from the Ph 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated CLL
  19. Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
  20. Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
  21. Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias
  22. Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703)
  23. Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis
  24. Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations
  25. Time To CAR T-Cell Therapy May Impact Outcomes For Patients With Relapsed/Refractory Large B-Cell Lymphoma In New CIBMTR Analysis
  26. Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat AML Populations
Tagged

Stay up-to-date with our biotech and Onco News

Facebook Linkedin Twitter

MedNess Plus

About Us

Disclaimer: The editors take care to share authentic information. In case of any discrepancies please write to newsletter @ medness.org
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.

Facebook Linkedin Twitter

Onco-This-Week

MedNess Plus

About Us

Disclaimer: The editors take care to share authentic information. In case of any discrepancies please write to newsletter @ medness.org
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.